13 June 2025 - Belgium-based UCB's novel psoriasis therapy, Bimzelx (bimekizumab), has officially entered Korea's competitive plaque psoriasis market with national health insurance coverage, positioning it as a new treatment option backed by a differentiated dual-action mechanism.

Korea’s Ministry of Health and Welfare began reimbursing Bimzelx as of 1 June 2025 for moderate to severe adult plaque psoriasis patients requiring phototherapy or systemic treatment. The reimbursement comes roughly 10 months after UCB filed for pricing in August last year.

Read Korea Biomedical Review article